Financials data is unavailable for this security.
View more
Year on year North China Pharmaceutical Co Ltd had revenues fall -3.62% from 10.50bn to 10.12bn, though the company grew net income from a loss of 689.23m to a gain of 4.89m.
| Gross margin | 29.56% |
|---|---|
| Net profit margin | 1.03% |
| Operating margin | 2.19% |
| Return on assets | 0.49% |
|---|---|
| Return on equity | 0.94% |
| Return on investment | 1.14% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at North China Pharmaceutical Co Ltd fell by 549.56m. However, the company earned 1.02bn from its operations for a Cash Flow Margin of 10.12%. In addition the company used 881.75m on investing activities and also paid 704.14m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.11 |
|---|---|
| Tangible book value per share | 0.6012 |
More ▼
Balance sheet in CNYView more
| Current ratio | 0.7694 |
|---|---|
| Quick ratio | 0.5403 |
| Total debt/total equity | 2.27 |
|---|---|
| Total debt/total capital | 0.6491 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 100.71%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
| Div yield(5 year avg) | 0.25% |
|---|---|
| Div growth rate (5 year) | -19.73% |
| Payout ratio (TTM) | 34.09% |
| EPS growth(5 years) | -50.13 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 107.24 |
More ▼
